425: Ikena Oncology and Inmagene Biopharmaceuticals to Merge, Securing $175 Million for Atopic Dermatitis Drug Development

Ikena Oncology and Inmagene Biopharmaceuticals have agreed to merge, with a $75 million private placement, to focus on developing IMG-007 for atopic dermatitis, creating a combined company with approximately $175 million in funding.

Summary

• Ikena Oncology and Inmagene Biopharmaceuticals have entered into a definitive merger agreement.
• The merger will be accompanied by a $75 million private placement, bringing the total funding for the combined company to approximately $175 million.
• The combined company, to be named ImageneBio, Inc., will focus on the development of IMG-007, a monoclonal antibody targeting OX40, for the treatment of atopic dermatitis.
• Pre-merger Inmagene equity holders are expected to own approximately 43.5% of the combined company, pre-merger Ikena equity holders are expected to own approximately 34.8%, and investors in the private placement are expected to own approximately 21.7%.
• The transaction is expected to close in mid-2025, pending customary closing conditions and shareholder approvals.
• Both Ikena and Inmagene shareholders will receive contingent value rights (CVRs) for their respective legacy assets.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with a focus on the potential of IMG-007 and the financial backing secured through the merger and private placement. The language is optimistic and highlights the differentiated profile of IMG-007 and the strong investor base.

Positives

• The merger will provide significant funding to advance the development of IMG-007.
• IMG-007 has a differentiated profile with a longer half-life and silenced ADCC function, potentially leading to improved efficacy and tolerability.
• The combined company will have a strong investor base, including both new and existing investors.
• The transaction is expected to close in mid-2025, providing a clear timeline for the merger.

Negatives

• The merger is subject to customary closing conditions, including shareholder approvals, which could delay or prevent the transaction from closing.
• The combined company will need to successfully execute its development plan for IMG-007 to realize its potential.
• The combined company will need to obtain sufficient additional capital to continue to advance its product candidates and preclinical programs.

Risks

• The merger is subject to customary closing conditions, including shareholder approvals, which could delay or prevent the transaction from closing.
• There is a risk that the combined company may not be able to obtain sufficient additional capital to continue to advance its product candidates and preclinical programs.
• There are uncertainties associated with Inmagenes platform technologies, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the commencement, enrollment and completion of clinical trials.
• There is a risk that the combined company may not realize certain anticipated benefits of the proposed merger, including with respect to future financial and operating results.
• There is a risk that the Concurrent Financing is not consummated.
• There is a risk that holders of CVRs may never receive any proceeds therefrom.

Future Outlook

The combined company will focus on the development of IMG-007, a monoclonal antibody targeting OX40, for the treatment of atopic dermatitis, with a Phase 2b clinical trial expected to begin in early 2025. The combined company plans to operate under the name ImageneBio, Inc. and trade on NASDAQ under the ticker IMA.

Management Comments

• We believe IMG-007 has the potential to be extremely impactful for patients with inflammatory diseases, while also building value for our shareholders.
• We are well-positioned to advance IMG-007 development and look forward to executing our development plan in atopic dermatitis and potentially additional indications.

Industry Context

The merger reflects a trend in the biopharmaceutical industry of companies combining resources to advance promising drug candidates, particularly in the immunology and inflammation space. The focus on OX40 as a target is also aligned with the growing interest in this pathway for treating inflammatory diseases.

Comparison to Industry Standards

• IMG-007 is a monoclonal antibody targeting OX40, a target that has been validated by other companies such as Amgen (rocatinlimab) and Sanofi (amlitelimab).
• IMG-007 has a longer half-life compared to other OX40-targeting mAbs in Phase 2 and later development, enabling its potential for dose and schedule optimization.
• IMG-007 has silenced antibody dependent cellular cytotoxicity (ADCC) function, and is non-T cell depleting, leading to a potentially improved tolerability profile relative to other mAbs in the class.
• The Phase 2a trial of IMG-007 showed a rapid and marked improvement from baseline in EASI, O-SCORAD and BSA scores as early as week 1, with progressive improvement over 20 weeks after the last dose, which is comparable to or better than results from other similar trials.
• The well-tolerated profile of IMG-007, potentially due to silenced ADCC function, is a key differentiator compared to other OX40-targeting mAbs, such as rocatinlimab, which has shown a common occurrence of pyrexia and chills in clinical trials.

Management Changes

Stakeholder Impact

• Ikena stockholders are expected to own approximately 34.8% of the combined company.
• Inmagene equity holders are expected to own approximately 43.5% of the combined company.
• Investors in the private placement are expected to own approximately 21.7% of the combined company.
• Both Ikena and Inmagene shareholders will receive contingent value rights (CVRs) for their respective legacy assets.
• The combined company will focus on the development of IMG-007, which has the potential to be impactful for patients with inflammatory diseases.

Next Steps

• The combined company will focus on the development of IMG-007, a monoclonal antibody targeting OX40, for the treatment of atopic dermatitis.
• A Phase 2b clinical trial for IMG-007 in atopic dermatitis is expected to begin in early 2025.
• The transaction is expected to close in mid-2025, subject to customary closing conditions and shareholder approvals.

Key Dates

Keywords

merger, acquisition, private placement, atopic dermatitis, IMG-007, OX40, monoclonal antibody, immunology, inflammation, biopharmaceutical